Evofem Biosciences (Evofem Biosciences) Accounts Receivable : $4.31 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Evofem Biosciences's accounts receivables for the quarter that ended in Mar. 2024 was $4.31 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Evofem Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 109.05.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Evofem Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-1.54.

Evofem Biosciences Accounts Receivable Historical Data

The historical data trend for Evofem Biosciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences Accounts Receivable Chart

Evofem Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

1.07

6.45

1.13

5.74

Evofem Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															7.40	5.20	6.32	5.74	4.31

Evofem Biosciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Evofem Biosciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Evofem Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.306	/	3.603	*	91
=	109.05

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Evofem Biosciences's accounts receivable are only considered to be worth 75% of book value:

Evofem Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0	+	0.75 * 4.306	+	0.5 * 1.306	-	78.883
-	0	-	0)	/	48.7104
=	-1.54

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Evofem Biosciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122

Website

https://www.evofem.com

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Executives

Yan Zhang	officer: Chief Financial Officer	6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar	director, 10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip	director	12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca	officer: Chief Commercial Officer	12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier	director, officer: Chief Executive Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: General Counsel and Secretary	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File	officer: Chief Financial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans	officer: Chief Commercial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd.	10 percent owner	1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd	10 percent owner	65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp	10 percent owner	767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell	officer: Chief Medical Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130